Table 4.
Emetogenic potential of single oral antineoplastic agentsa
| High/moderate | Abemaciclib | Lenvatinib |
| Adagrasib | Lomustine | |
| Avapritinib | Midostaurin | |
| Bosutinib | Mobocertinib | |
| Cabozantinib | Niraparib | |
| Ceritinib | Olaparib | |
| Crizotinib | Procarbazine | |
| Cyclophosphamide | Ribociclib | |
| Enasidenib | Rucaparib | |
| Fedratinib | Selinexorb | |
| Hexamethylmelamine (altretamine) | Temozolomide | |
| Imatinib | Vinorelbine | |
| Low/minimal | Acalabrutinib | Methotrexate |
| Afatinib | Neratinib | |
| Alectinib | Nilotinib | |
| Alpelisib | Nintedanib | |
| Apalutamide | Olutasidenib | |
| Asciminib | Osimertinib | |
| Axitinib | Palbociclib | |
| Bexarotene | Panobinostat | |
| Brigatinib | Pazopanib | |
| Capecitabine | Pemigatinib | |
| Capmatinib | Pexidartinib | |
| Chlorambucil | Pomalidomide | |
| Cobimetinib | Ponatinib | |
| Dabrafenib | Pralsetinib | |
| Dacomitinib | Regorafenib | |
| Darolutamide | Relugolix | |
| Dasatinib | Ripretinib | |
| Duvelisib | Ruxolitinib | |
| Encorafenib | Selpercatinib | |
| Entrectinib | Sonidegib | |
| Erdafitinib | Sorafenib | |
| Erlotinib | Sotorasib | |
| Estramustine | Sunitinib | |
| Etoposide | Talazoparib | |
| Everolimus | Tazemetostat | |
| Fludarabine | Tegafur–uracil | |
| Futibatinib | Tepotinib | |
| Gefitinib | Thalidomide | |
| Gilteritinib | Tioguanin (6-thioguanine) | |
| Glasdegib | Tivozanib | |
| Hydroxyurea | Topotecan | |
| Ibrutinib | Trametinib | |
| Idelalisib | Trifluridine–tipiracil | |
| Infigratinib | Tucatinib | |
| Ivosidenib | Umbralisib | |
| Ixazomib | Vandetanib | |
| Lapatinib | Vemurafenib | |
| Larotrectinib | Venetoclax | |
| Lenalidomide | Vismodegib | |
| Lorlatinib | Vorinostat | |
| Melphalan (L-phenylalanine mustard) | Zanubrutinib |
a
Classified emetic potential of oral agents based on a full course of therapy and not a single dose within the first cycle.
b
Emetic potential appears to be at the high end of the moderate category.